NCT00668785View on ClinicalTrials.gov

Intravitreal Ranibizumab to Treat Macular Edema After Panretinal Photocoagulation (Phase II)

PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

June 30, 2010

Study Completion Date

March 31, 2012

Conditions
Proliferative Diabetic RetinopathyMacular Edema
Interventions
DRUG

ranibizumab

Ranibizumab 0.5mg at baseline and then again at 30 days and/or 60 days after PRP as deemed appropriate by the Investigator.

Trial Locations (1)

94107

West Coast Retina Medical Group Inc., San Francisco

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Jumper, J. Michael, M.D.

INDIV